serum
level
gamma
interferon
tumor
necrosi
factor
alpha
pneumon
plagu
patient
determin
enzymelink
immunosorb
assay
elev
cytokin
patient
level
increas
clear
time
cours
indic
might
prognost
marker
predict
progress
plagu
human
plagu
case
clinic
repres
three
form
bubon
septicem
pneumon
depend
rout
infect
pneumon
plagu
threaten
form
diseas
high
mortal
without
time
effect
treatment
juli
deadli
primari
pneumon
plagu
ppp
hit
xinghai
counti
qinghai
provinc
china
confirm
case
death
outbreak
investig
clinic
epidemiolog
bacteriolog
immunolog
method
within
day
onset
symptom
patient
treat
streptomycin
ceftriaxon
sodium
ciprofloxacin
day
except
one
treat
day
although
pneumon
plagu
report
unit
state
india
uganda
zambia
ecuador
madagascar
report
inflammatori
cytokin
respons
yersinia
pesti
pneumon
plagu
patient
retrospect
investig
investig
dynam
serum
cytokin
nine
pneumon
plagu
patient
reveal
relationship
cytokin
product
diseas
cours
thirtysix
serum
sampl
nine
patient
collect
day
onset
clinic
symptom
control
serum
sampl
obtain
healthi
herdsmen
symptom
patient
obvious
allevi
week
antibiot
treatment
indic
end
acut
phase
ppp
suggest
sampl
day
later
acut
phase
sampl
day
earli
convalesc
stage
serum
level
gamma
interferon
tumor
necrosi
factor
alpha
measur
highsensit
enzymelink
immunosorb
assay
elisa
bender
medsystem
accord
manufactur
instruct
differ
cytokin
level
pneumon
plagu
patient
healthi
control
reveal
analysi
varianc
anova
sar
softwar
cytokin
concentr
variou
time
point
compar
student
test
probabl
valu
consid
signific
among
six
cytokin
measur
elisa
elev
level
observ
pneumon
patient
time
point
p
moreov
product
declin
convalesc
phase
patient
differ
concentr
patient
healthi
control
p
fig
patient
communityacquir
pneumonia
cap
caus
mycoplasma
pneumonia
chlamydia
pneumonia
streptococcu
pneumonia
viru
patient
sever
acut
respiratori
syndrom
sar
pneumonia
cytokin
respons
investig
pesti
caus
sever
pneumonia
human
anim
given
inhal
rout
comparison
serum
cytokin
respons
among
patient
cap
sar
pneumonia
plagu
pneumonia
reveal
signific
differ
serum
cytokin
profil
seem
elev
cytokin
patient
pneumonia
caus
pesti
pneumonia
unfortun
two
cytokin
detect
patient
cap
caus
pneumonia
could
compar
chang
patient
pneumonia
caus
pesti
pneumonia
interestingli
serum
concentr
significantli
elev
patient
infect
pneumonia
c
pneumonia
influenza
viru
pneumonia
sar
viru
pesti
result
provid
evid
notion
elev
concentr
correl
degre
sever
inflamm
rather
specif
etiolog
agent
pneumonia
therefor
might
prognost
marker
predict
progress
pneumon
plagu
multifunct
proinflammatori
cytokin
produc
blood
leukocyt
endotheli
cell
within
injur
lung
tissu
therefor
elev
serum
product
level
might
origin
injur
pulmonari
bronchial
alveolar
epitheli
cell
likewis
elev
level
might
releas
endotheli
cell
within
injur
lung
tissu
pneumon
plagu
patient
found
level
elev
sar
patient
elev
level
observ
patient
pneumonia
caus
pneumonia
c
pneumonia
influenza
viru
anim
experi
pesti
could
strongli
suppress
endogen
product
mice
elev
product
plagu
patient
product
significantli
increas
mice
rat
h
infect
aerosol
pesti
indic
might
differ
cytokin
profil
human
rodent
howev
intranas
infect
mous
model
pneumon
plagu
gene
encod
varieti
cytokin
upregul
earli
phase
h
postinfect
infect
downregul
middl
phase
h
postinfect
indic
inhibit
host
defens
system
develop
plagu
unfortun
due
sudden
outbreak
serum
sampl
patient
collect
earlier
stage
therefor
cytokin
concentr
qinghai
plagu
patient
infect
anim
aerosol
pesti
earli
acut
phase
ppp
avail
comparison
sinc
associ
cytokin
concentr
patient
sex
histori
antibiot
document
cap
patient
could
determin
whether
measur
level
cytokin
wane
due
treatment
antibiot
differ
patient
age
sex
preliminari
investig
product
undetect
plagu
patient
consist
result
sera
mice
infect
pesti
intranas
rout
